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Abstract  46 
Background: First-trimester miscarriage affects up to a quarter of women worldwide. With 47 
many competing treatment options available, there is a need for a comprehensive evidence 48 
synthesis. 49 
Objectives and rationale: We conducted a systematic review and network meta-analysis to 50 
assess the effectiveness and safety of treatment options for first-trimester miscarriage: 51 
expectant management (EXP), sharp dilation and curettage (D+C), electric vacuum aspiration 52 
(EVAC), manual vacuum aspiration (MVA), misoprostol alone (MISO), 53 
mifepristone+misoprostol (MIFE+MISO) and misoprostol plus electric vacuum aspiration 54 
(MISO+EVAC).  55 
Search methods: We searched MEDLINE, Embase, CINAHL, AMED and Cochrane 56 
Library from inception till June 2018. We included randomised trials of women with first-57 
trimester miscarriage (<14 weeks gestation) and conducted a network meta-analysis 58 
generating both direct and mixed evidence on the effectiveness and side effects of available 59 
treatment options. The primary outcome was complete evacuation of products of conception. 60 
We assessed the risk of bias and the global network inconsistency. We compared the surface 61 
under the cumulative ranking curve (SUCRA) for each treatment. 62 
Outcomes: A total of 46 trials (9250 women) were included. The quality of included studies 63 
was overall moderate with some studies demonstrating a high risk of bias. We detected 64 
unexplained inconsistency in evidence loops involving MIFE+MISO and adjusted for it. EXP 65 
had lower effectiveness compared to other treatment options. The effectiveness of medical 66 
treatments was similar compared to surgery. Mixed evidence of low confidence suggests 67 
increased effectiveness for MIFE+MISO compared to MISO alone (RR 1.49, 95% CI 1.09-68 
2.03). Side effects were similar among all options. Fewer women needed analgesia following 69 
EVAC compared to MISO (RR for MISO 0.43, 95% CI 0.27-0.68) and in the EXP group 70 
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compared to EVAC (RR 2.07, 95% CI 1.25-3.41). MVA had higher ranking (low likelihood) 71 
for post-treatment infection and serious complications (SUCRA 87.6%, 79.2%respectively) 72 
with the highest likelihood for post-treatment satisfaction (SUCRA 98%). 73 
Wider implications: Medical treatments for first-trimester miscarriage have similar 74 
effectiveness and side effects compared to surgery. The addition of MIFE could increase the 75 
effectiveness of MISO and reduce side effects, although evidence is limited due to 76 
inconsistency. EXP has lower effectiveness compared to other treatment options. 77 
 78 
Systematic review registration: Prospero CRD42016048920 79 
 80 
Keywords: miscarriage, pregnancy loss, first trimester, effectiveness, woman, systematic 81 
review, network meta-analysis. 82 
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Introduction 84 
First trimester miscarriage, the most common time of  pregnancy loss, is estimated to affect 85 
up to a quarter of pregnant women in their lifetime (Wang et al., 2003). Miscarriage can lead 86 
to significant clinical and emotional morbidity, affecting the couples’ quality of life (Jurkovic 87 
et al., 2013). Providing patient-centred care can help to reduce the psychological squelae 88 
associated with miscarriage (van den Berg et al., 2017) such as increased anxiety, depression, 89 
grief and low self-esteem (Frost and Condon, 1996; Swanson et al., 2009). The burden of 90 
miscarriage on healthcare resources is significant, leading to over 50,000 hospital admissions 91 
annually in the UK (The National Institute for Health and Care Excellence, 2012), with a 92 
similar impact in other developed countries (Queensland Clinical Guidelines, 2015; The 93 
American College of Obstetricians andGynecologists, 2015).  94 
 95 
Various treatment options exist for couples experiencing first-trimester miscarriage; these are 96 
broadly categorised into expectant, medical and surgical groups (Trinder et al., 2006). The 97 
wide use of less invasive treatments such as prostaglandins and manual vacuum evacuation 98 
could reduce the need for surgical interventions under general anaesthesia and the number of 99 
hospital admissions (Jurkovic et al., 2013; Sotiriadis et al., 2005). Misoprostol is currently 100 
the most used drug for treating miscarriage, however, there is no consensus on the best dose 101 
and route of its administration (Neilson et al., 2013). Combining medical and surgical 102 
treatments is common, though evidence to support this practice is imprecise (Fang et al., 103 
2009). Evidence concerning the effectiveness and safety of available treatment options is 104 
limited to pairwise comparisons in randomised trials and their meta-analyses (Nanda et al., 105 
2006; Neilson et al., 2013; Sotiriadis et al., 2005; Tunçalp et al., 2010).  106 
 107 
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There is a need for a comprehensive evidence synthesis to compare the effectiveness and 108 
safety of the available treatment options. We conducted a systematic review and a network 109 
meta-analysis of randomised trials (comparing different treatments for a particular condition 110 
using the estimated effect size from direct and indirect comparisons) (Al Wattar et al., 2017) 111 
to assess the effectiveness and side effects of available treatment options for complete 112 
evacuation of products of conception in women experiencing first-trimester miscarriage.    113 
 114 
Methods 115 
We conducted our systematic review according to a prospectively registered protocol 116 
(Prospero CRD42016048920) and reported the findings to comply with the extended 117 
PRISMA guidelines (Hutton et al., 2015). The final author affirms that the manuscript is an 118 
honest, accurate, and transparent account of the study being reported; no important aspects of 119 
the study have been omitted; and there are no discrepancies from the planned study protocol.  120 
 121 
Search strategy  122 
We searched the following electronic databases for randomised trials comparing any 123 
treatment option for first-trimester miscarriage from inception until June 2018 (MEDLINE, 124 
Embase, CINAHL, AMED and Cochrane Library). We developed a multi-step search 125 
strategy and adjusting it appropriately for each database (not shown). No search filters were 126 
applied. We conducted supplementary searches in Google Scholar and Scopus. We manually 127 
screened bibliographies of reviewed articles to identify any additional relevant trials. Articles 128 
in non-English language were obtained and translated if deemed relevant. We contacted 129 
authors for further information when needed, but no unpublished data were included. We 130 
reviewed all available systematic reviews on the management of first-trimester miscarriage to 131 
identify any additional studies. 132 
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 133 
Selection criteria and data extraction 134 
We included all randomised trials that evaluated any treatment option in women with first-135 
trimester miscarriage (defined as a spontaneous loss of a non-viable intrauterine pregnancy 136 
between 0 and 14 weeks’ gestation) (The National Institute for Health and Care Excellence, 137 
2012). Studies that included a combination of two treatment options (e.g. medical plus 138 
surgical) were included. Studies with multiple comparison arms were also included. We 139 
excluded quasi-randomised studies and those reporting on elective termination of pregnancy. 140 
Studies that compared variations of the same treatment in both arms (e.g. misoprostol 400 µg 141 
vs misoprostol 600 µg) were reported narratively and excluded from the meta-analysis. 142 
Studies that reported on secondary outcomes only were also excluded.  143 
We manually extracted data, using a bespoke electronic tool, on the place of the study, the 144 
publication journal, treatment settings, population characteristics, the treatment options 145 
evaluated, including its dose and route where applicable, and primary and secondary 146 
outcomes. The selection and data extraction processes were conducted in duplicate by two 147 
independent reviewers (BHA and NM). Any disagreement was resolved by discussion with a 148 
third reviewer (KSK).  149 
 150 
Primary and secondary outcomes   151 
Our primary outcome was complete evacuation of products of conception, defined clinically 152 
or on ultrasound as an empty uterine cavity without the need for further treatment. Secondary 153 
outcomes were: serious complications (defined as a composite of any of the following: 154 
uterine perforation, cervical tear, hysterectomy, laparotomy, Asherman’s syndrome, and 155 
death), need for blood transfusion, post-treatment infection/pelvic inflammatory disease, 156 
nausea, vomiting, diarrhoea, fever (>38 ºC with no evidence of infection), patient 157 
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satisfaction, mean hospital stay (days), visual analogue pain scores, anxiety, depression and 158 
need for analgesia.  159 
 160 
Types of treatment for first trimester miscarriage 161 
Treatment options were grouped into five categories: expectant (defined as conservative 162 
management with no active intervention including placebo), medical (defined as any medical 163 
drug of any dose, route and format to achieve uterine evacuation), placebo (defined as a 164 
planned placebo intervention within a trial settings), surgical (defined as any surgical 165 
instruments used under general or local anaesthesia to achieve uterine evacuation) and a 166 
combination of any medical plus surgical treatment used consecutively. To reduce 167 
inconsistency in the network, we combined conservative and placebo treatments under the 168 
same label (expectant management). We also excluded uncommon medical drugs that were 169 
reported in single studies (e.g. Methotrexate) and reported on them narratively.  170 
 171 
Quality assessment of risk of bias 172 
We assessed the risk of bias in all included studies in duplicate by two independent reviewers 173 
(BHA and NM) using the Cochrane risk of bias assessment tool (Higgins et al., 2011). This 174 
included assessment of the following items: randomisation and sequence generation, 175 
allocation concealment, blinding and performance, outcome assessment, completeness of 176 
outcome data and selective outcome reporting. Unblinded studies were not penalised in the 177 
risk of bias assessment due to the nature of the treatments that makes blinding non-feasible. 178 
Quality assessment was performed in duplicate by two independent reviewers.   179 
 180 
Statistical analysis  181 
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We performed standard pairwise meta-analyses using a random-effects model (Sutton et al., 182 
2000) and network meta-analysis within a frequentist framework with multivariate meta-183 
analysis models (White et al., 2012), exploiting the direct and indirect randomised evidence 184 
to determine the relative effects and ranking. We reported on direct evidence (from head to 185 
head comparison of treatments) and mixed evidence (combining both direct and indirect 186 
evidence from comparison of treatments) using weighted mean difference (WMD) for 187 
continuous outcomes and risk ratios (RR) for dichotomous outcomes with 95% confidence 188 
intervals (CI). We also computed the probability that each treatment is the most effective, as 189 
well as the surface under the cumulative ranking curve (SUCRA) to compare the relative 190 
ranking probability of each treatment (Chaimani et al., 2013; Salanti et al., 2011). Providing 191 
a cumulative rankogram adjusts for any uncertainty in the relative treatment effect where 192 
limited evidence exists (Chaimani et al., 2013). A cumulative rank provides the probability 193 
for each treatment to be the best among the rang of available treatment options; the SUCRA 194 
is a transformation of the mean rank accounting for the location and variance of available 195 
treatment effects to generate a treatment hierarchy (Salanti et al., 2011).  196 
In pairwise meta-analyses, we estimated different heterogeneity variances for each pairwise 197 
comparison, using the I² index, to capture the percentage of variation that is not due to 198 
chance. In the network meta-analysis, we assumed a common estimate for the heterogeneity 199 
variance across the different comparisons. To check the assumption of consistency in the 200 
entire network, we used the design-by-treatment model (Higgins et al., 2012). In case of 201 
whole network inconsistency, we investigated differences between direct and indirect 202 
evidence using the loop-specific approach (Bucher et al., 1997), assuming a common 203 
heterogeneity estimate within each loop (a loop of evidence exist when numerous trials 204 
compare a minimum of three treatments e.g A vs B vs C) (Veroniki et al., 2013). We 205 
investigated any detected inconsistency and adjusted for unexplained inconsistency within the 206 
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network using established models in STATA (Riley et al., 2017). All analyses were done 207 
using STATA statistical software, release 14 (StataCorp, College Station, TX, 208 
2015).(Chaimani et al., 2013; White, 2011; White et al., 2012). 209 
 210 
Patient involvement 211 
We did not involve a patient representative in the design of our study. We consulted the 212 
James Lind Library and previous Cochrane reviews to identify the primary outcome and 213 
other outcomes of interest to stakeholders.  214 
 215 
Results 216 
Characteristics of included studies 217 
Our electronic search identified 3648 potentially relevant studies. Of these, we excluded 3523 218 
after reviewing titles and abstracts. The remaining 125 studies were assessed in full. Eleven 219 
studies were identified from screening bibliographies and were assessed in full. We excluded  220 
90 studies: five reporting on the use of methotrexate, dinoprestone, mifepreistone alone, 221 
laminaria, gemeprost (Autry et al., 1999; Al Inizi and Ezimokhai, 2003; Johnson et al., 1997; 222 
Lelaidier et al., 1993),  20 comparing different dosages, routes or formats of misoprostol 223 
against each other, 15 non- or quasi-randomised, 16 not meeting the inclusion criteria and 34 224 
not reporting the primary outcome. In total 46 randomised trials reporting on 9250 women 225 
were included, of these two were in Portuguese (Holanda et al., 2003; Pereira et al., 2006) 226 
and one in Norwegian (Karlsen, Jørn-Hugo; Hjalmar, 2001) (Figure 1). 227 
A third of included trials were conducted in European countries (14/46, 30.4%) and fourteen 228 
in Asian countries (14/46, 30.4%). Most studies included a two arms comparison and four 229 
included three arms. The median study sample size was 60 (range 12-402). The majority of 230 
trials were conducted in tertiary healthcare settings (35/46, 76.1%). One study was conducted 231 
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in outpatient settings. Eight were multicentre randomised trials (8/46, 17.3%). Table I 232 
provides a summary of the characteristics of included trials.   233 
 234 
Risk of bias 235 
The quality of included studies was overall moderate with some studies demonstrating a high 236 
risk of bias (Supplementary Figure S1). Nine studies had a high risk of bias for randomisation 237 
(9/46, 19.5%) and ten (10/46, 21.7%) had a high risk of bias for allocation concealment. 238 
Outcomes assesment (i.e. attrition) was judged to have a high risk of bias in six studies, and 239 
was inadequate in 15 studies (15/46, 32.6%) but good in 25 studies (25/41, 60.9%). Six 240 
studies had a high risk of bias for detection (i.e. selective reporting) (6/46, 13%) and 14 had a 241 
high risk of bias in outcomes reporting (i.e. incomplete  data) (14/46, 30.4%). Conflict of 242 
interest was declared as not present in only seven studies (7/46, 15.2%) and was not reported 243 
on in the remaining studies. Only four studies were double blinded and these were studies 244 
comparing medical treatments to placebo (3/46, 6%) (Bagratee et al., 2004; Blohm et al., 245 
2005; Lister et al., 2005; Sinha et al., 2018). A summary of risk of bias assessment on 246 
included trials is provided in Supplementary Table SII.  247 
 248 
Primary outcome 249 
Our network for the primary outcome included 46 randomised trials (9250 women) 250 
comparing seven treatment options: expectant management (EXP)(19 trials, 1587 women), 251 
sharp dilation and curettage (D+C)(5 trials, 247 women) , electric vacuum aspiration under 252 
general anaesthesia (EVAC)(19 trials, 1766 women), manual vacuum aspiration under local 253 
anaesthesia (MVA)(12 trials, 1671 women), misoprostol alone (MISO)(32 trials, 3017 254 
women), mifepristone + misoprostol (MIFE+MISO)(9 trials, 932 women), sequential 255 
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misoprostol + electric vacuum aspiration under general anaesthesia (MISO+EVAC)(1 trial, 256 
30 women) (Figure 2).  257 
Both direct and mixed evidence supported the overall inferiority of EXP compared to most 258 
treatment options for achieving complete evacuation of products of conception (EXP vs 259 
MISO RR 0.76, 95% CI 0.65-0.89; EXP vs EVAC RR 0.68, 95% CI 0.59-0.79; EXP vs D+C 260 
RR 0.73, 95% CI 0.57-0.94; MISO+EVAC vs EXP RR 1.35, 95% CI 1.10-1.66; MVA vs 261 
EXP RR 1.46, 95% CI 1.19-1.79) (Figure 3). All surgical treatments (MVA, EVAC and 262 
D+C) demonstrated similar effectiveness for achieving the primary outcome. This was also 263 
the case when comparing MISO against each of the surgical treatment options (MVA vs 264 
MISO RR 1.10, 95% CI 0.92-1.33; EVAC vs MISO RR 1.11, 95% CI 0.97-1.27; D+C vs 265 
MISO RR 1.03, 95% CI 0.82-1.30). Direct evidence on the use of MISO+EVAC was drawn 266 
from one trial only (MISO+EVAC vs MISO, RR 2.86, 95% CI 1.45-5.64; data not shown) 267 
and mixed evidence supports its superiority only over EXP (RR 1.35, 95% CI 1.10-1.66). 268 
Mixed evidence did not support the use of MIFE+MISO compared to using MISO alone to 269 
increase effectiveness (RR 1.43, 95% CI 0.87-2.36). However, we detected significant 270 
inconsistency between direct and mixed evidence for MISO vs MISO+EVAC; EVAC vs 271 
MISO; EVAC vs EXP; EVAC vs MIFE+MISO and EXP vs MISO (Supplementary Table 272 
SI). The overall by network inconsistency analysis was significant at p=0.003. Adjusting for 273 
inconsistency, mixed evidence favoured the addition of MIFE to MISO to improve 274 
effectiveness (MIFE+MISO vs MISO RR 1.49, 95% CI 1.09-2.03) in contrast to 275 
MISO+EVAC vs MISO (RR 0.63, 95% CI 0.51-0.79) (Supplementary Figure S3).  276 
 277 
The surface under the cumulative ranking curve for treatment effectiveness was highest for 278 
MIFE+MISO (SUCRA 89.3%) followed by EVAC (SUCRA 76.2%). EXP was ranked as the 279 
least effective treatment (SUCRA 24%) (Figure 4). Visual analysis of our funnel plot 280 
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demonstrates a reasonable distribution of effect size with limited evidence of small study 281 
effect (Supplementary Figure S4). 282 
 283 
Secondary outcomes 284 
Meta-analysis of mixed evidence demonstrated no difference for any of the following 285 
outcomes between medical and surgical treatment options: need for blood transfusion, post-286 
treatment infection, serious complications, diarrhoea, vomiting, nausea and fever 287 
(Supplementary Figures S5-11). Compared to MISO, MIFE+MISO was associated with a 288 
lower risk ratio for developing fever (RR 0.33, 95% CI 0.19-0.57), nausea (RR 0.42, 95% CI 289 
0.24-0.72) and vomiting (RR 0.55, 95% CI 0.32-0.94). Fewer women needed analgesia post 290 
treatment in the EVAC group compared to MISO (RR 0.43, 95% CI 0.27-0.68). Those who 291 
opted for EXP also used more analgesia compared to EVAC (RR 2.07, 95% CI 1.25-3.41) 292 
(Supplementary Figure S12). Women’s satisfaction was similar for all the treatment options 293 
(Supplementary Figure S13). Supplementary Table SIII provides a summary of effect 294 
estimates for all secondary outcomes across treatment options. 295 
 296 
Table II summaries the calculated SUCRA and mean rank for the secondary outcomes by the 297 
treatment options. Generally, MIFE+MISO had high ranking (low likelihood) for causing 298 
common gastrointestinal (GI) side effects (nausea (SUCRA 93.1%), vomiting (SUCRA 84%) 299 
and diarrhoea (SUCRA 63.2%)) and fever (SUCRA 86.8%). MVA had higher ranking (low 300 
likelihood) for post-treatment infection (SUCRA 87.6%) and serious complications (SUCRA 301 
79.2%) with the highest likelihood for post-treatment satisfaction (SUCRA 98%). Women 302 
opting for EVAC had higher likelihood of requiring post-treatment blood transfusion 303 
(SUCRA 14.7%).  304 
 305 
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Discussion 306 
Main findings 307 
Our comprehensive meta-analysis showed that for managing first-trimester miscarriage, EXP 308 
had lower effectiveness to achieve complete evacuation of products of conception compared 309 
to other treatment options. Overall, there was similar effectiveness for the medical 310 
(MIFE+MISO and MISO) and the surgical options (MVA, D+C, and EVAC), with similar 311 
safety profiles reported. There was limited evidence to support the use of MISO+EVAC with 312 
no information on its safety profile. Evidence on the use of MIFE+MISO suffered from 313 
significant inconsistency. Overall, the addition of MIFE to MISO seems to improve its 314 
effectiveness with reduced likelihood of side effects but more research is needed to address 315 
the perceived inconsistency between direct and indirect evidence. Women’s satisfaction was 316 
similar for all the options compared.    317 
 318 
Currently, EXP is recommended as the first-line treatment option for first-trimester 319 
miscarriage (The National Institute for Health and Care Excellence, 2012). Women opting for 320 
this approach should be counselled objectively about the chances of needing further 321 
treatment, potential complications such as requiring blood transfusion (SUCRA 36.3%) or 322 
more analgesia (SUCRA 37.4%), and the availability of other effective treatment options. 323 
Excessive bleeding and repeated blood transfusion contribute to prolonged hospital stays and 324 
long-term adverse outcomes such as alloimmunisation (Royal College of Obstetricians and 325 
Gynaecologists, 2015) which are infrequently assessed in randomised trials.  326 
 327 
Strength and limitations 328 
This review, to our knowledge, is the first to provide a comprehensive evidence synthesis 329 
with network meta-analysis on all current treatment options for first-trimester miscarriage. 330 
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We conducted a systematic review of the literature with no search limitations. We assessed 331 
and found little evidence of small study effect with the funnel plot analysis raising confidence 332 
in our findings. We assessed the risk of bias using the Cochrane risk of bias assessment tool 333 
(Higgins et al., 2011) which demonstrated low to moderate risk of bias in the majority of 334 
included studies. Compared to previously conducted meta-analysis (Nanda et al., 2006; 335 
Neilson et al., 2006,  2013; Sotiriadis et al., 2005; Wen et al., 2008), our study provides 336 
higher confidence supporting the role of medical treatment options for first trimester 337 
miscarriage, incorporating indirect evidence and ranking treatments likelihood for 338 
effectiveness and side effects.   339 
 340 
Our findings are not without limitations. We were unable to accommodate for potential effect 341 
modifiers such as variation in population characteristics relevant to age, parity, size of 342 
products of conception, presence of side effects before randomisation and treatment settings. 343 
A large gestation sac might require a higher doses of MISO to achieve complete evacuation 344 
(Neilson et al., 2006). Evidence on some treatment options, such as MVA, was sought 345 
primarily from low/middle income countries, which could suggest variations in local practice 346 
and geographical bias to one treatment option over the others. 347 
  348 
There were variations in the ultrasound criteria used to diagnose the type of miscarriage 349 
(missed vs incomplete) and the primary outcome of complete evacuation of products of 350 
conception. The use of a standardised ultrasound criteria for the diagnosis of miscarriage is 351 
only recent and some of the included trials pre-date the currently established guidelines  352 
(The National Institute for Health and Care Excellence, 2012). To be pragmatic, we opted to 353 
keep those trials and offer a comprehensive and accurate review of the available literature. 354 
Similarly, there was variation in the type of included miscarriages (missed vs incomplete) in 355 
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each trial with some trials randomising either or both or simply not reporting on it (Table 1). 356 
Due to the risk of inconsistency, we were unable to generate evidence on the management of 357 
each type of miscarriage and our findings remain pragmatic. Such variation could be best 358 
addressed using an individual participant data meta-analysis. 359 
 360 
There was inconsistency within the network (Supplementary Table SI) specifically within 361 
evidence loops comparing MIFE+MISO to other treatment options. We were unable to 362 
attribute this inconsistency to a particular effect modifier and adjusted for it using established 363 
models. Inconsistency could be attributed to the variations in the dosages and the routes of 364 
administration of MISO among included trials. Typically, MISO is used in sequential doses 365 
of 200 mcg and stopped once complete evacuation of products is achieved; this could present 366 
inherent inconsistency among trials. Quality evidence on the most effective dose with the 367 
least side effect is yet to emerge (Neilson et al., 2006).  368 
 369 
Variations in defining endpoints and the follow-up period limited the information on 370 
important long term outcomes such as uterine adhesions, pre-term birth and future fertility. 371 
Recent evidence suggest an increased risk for pre-term birth with multiple dilation and 372 
curettage (Lemmers et al., 2015). Future work should focus on following up randomised 373 
cohorts to capture such outcomes.  374 
 375 
To be pragmatic, evidence on MISO+EVAC, sought from one trial (Fang et al., 2009), was 376 
kept within our network in view of its wide use in current practice. The findings of this trial 377 
should be interpreted with caution due to its small sample size, moderate risk of bias and 378 
limited reporting on secondary outcomes. We planned to report on four additional outcomes 379 
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in our protocol (hospital stay, changes in haemoglobin, anxiety, and depression). This, 380 
however, was not possible due to the large variability in reported end points.  381 
We judged blinding to be possible in seven studies (Bagratee et al., 2004; Blohm et al., 2005; 382 
Herabutya and O‐Prasertsawat, 1997; Lister et al., 2005; Ngai et al., 2001; Nielsen et al., 383 
1999; Wood and Brain, 2002). Of these, only four (Bagratee et al., 2004; Blohm et al., 2005; 384 
Lister et al., 2005; Sinha et al., 2018) were blinded, introducing a potential risk of bias. Lack 385 
on information on blinding for outcomes assessment is another limitation in the included 386 
studies.  387 
 388 
Interpretation of findings  389 
Our study supports the use of medical treatments as a potential substitute for surgery, 390 
however, studies to establish the lowest effective dose of MISO are needed (Neilson et al., 391 
2006). A higher dose of MISO is likely to cause more side effects such as nausea and 392 
vomiting (Tang et al., 2007). Medical management could be considered as a cost-effective 393 
first-line treatment option. The woman’s preference is an important factor to consider when 394 
offering the various treatment options, often influenced by their carer’s advice. There was 395 
seldom consideration in the included studies for reporting outcomes important to the women 396 
undergoing miscarriage, such as post-treatment anxiety and depression. None of the included 397 
studies reported on the tolerability of each treatment option which can aid women to identify 398 
their preferred choice. Developing a core outcome set with input from all stakeholders should 399 
be considered in future research (Khan, 2016).   400 
 401 
Recently, MIFE has been more commonly combined with MISO to improve the effectiveness 402 
of medical treatment for uterine evacuation (Spitz et al., 1998). Our analysis, seeking direct 403 
and mixed evidence, suggests some added value compared to using MISO alone for first-404 
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trimester miscarriage but with limited confidence due to the perceived inconsistency among 405 
included trials. Considering its high cost, a cost-effectiveness evaluation is needed to 406 
establish the value of using MIFE+MISO routinely. Using MISO for priming the cervix 407 
before EVAC has been suggested to reduce the need for dilation and trauma to the 408 
endometrium (Lawrie et al., 1996). Evidence to support the effectiveness and safety of this 409 
practice for managing first trimester miscarriage is scarce (only one randomised trial of 75 410 
women) (Fang et al., 2009) and more trials are needed to justify the potentially increased cost 411 
and side effects.   412 
 413 
Outpatient use of MVA with direct access to operating theatres could offer cost reduction 414 
(Magotti et al., 1995). While EXP is arguably cheaper than other treatment options, the 415 
higher probability of complications might increase its associated cost. There is a need for a 416 
comprehensive economic evaluation with extended decision models to accommodate for the 417 
effectiveness of all available treatment options and potential adverse outcomes (Strand, 418 
2015). Comprehensive policymaking including all available treatment options could offer 419 
better value for money and facilitate higher patient satisfaction (Dalton et al., 2015; Molnar et 420 
al., 2000; Wallace et al., 2010) (Supplementary Figure S2). 421 
 422 
Our study provides important insight for various stakeholders involved in caring for women 423 
with first trimester miscarriage. Future work should aim to involve stakeholders’ views 424 
prospectively on relevant health outcomes to provide safe and cost-effective care. Efforts to 425 
standardise treatment options and reduce selective reporting of outcomes are warranted to 426 
reduce inconsistency in evidence synthesis.  427 
 428 
Conclusions 429 
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Medical treatments for first-trimester miscarriage have similar effectiveness and side effects 430 
compared to surgery. The addition of MIFE could increase the effectiveness of MISO and 431 
reduce side effects though evidence is limited due to inconsistency. EXP has lower 432 
effectiveness compared to other treatment options. 433 
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Figures and tables legends: 453 
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Figure 1: The study selection process for network meta-analysis on management of first 454 
trimester miscarriage. 455 
 456 
Figure 2: Network of treatment options for first trimester miscarriage. Options: 457 
expectant management (EXP), sharp dilation and curettage (D+C), electric vacuum aspiration 458 
(EVAC), manual vacuum aspiration (MVA), misoprostol alone (MISO), 459 
mifepristone+misoprostol (MIFE+MISO) or misoprostol+electric vacuum aspiration 460 
(MISO+EVAC).  461 
The size of the dots represents the number of women randomised to each treatment option 462 
and the thickness of the lines represents the number of randomised trials with head to head 463 
comparison between each two treatment options. 464 
 465 
Figure 3: Direct (D) and mixed (M) evidence meta-analysis for treatment options for 466 
first trimester miscarriage. Options: expectant management (EXP), sharp dilation and 467 
curettage (D+C), electric vacuum aspiration (EVAC), manual vacuum aspiration (MVA), 468 
misoprostol alone (MISO), mifepristone+misoprostol (MIFE+MISO) or misoprostol+electric 469 
vacuum aspiration (MISO+EVAC).  470 
 471 
Figure (4): The mean rank and cumulative rank probability (SUCRA) of effectiveness 472 
for each treatment option for first trimester miscarriage. Options: expectant management 473 
(EXP), sharp dilation and curettage (D+C), electric vacuum aspiration (EVAC), manual 474 
vacuum aspiration (MVA), misoprostol alone (MISO), mifepristone+misoprostol 475 
(MIFE+MISO) or misoprostol+electric vacuum aspiration (MISO+EVAC).  476 
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Treatments with the top mean rank and the largest area under the curve have the highest 477 
probability of achieving the primary outcome of complete evacuation of products of 478 
conception. 479 
 480 
Table I: Characteristics of included trials evaluating treatment options for first 481 
trimester miscarriage. 482 
 483 
Table II: Summary of the calculated mean rank and the surface under the cumulative 484 
ranking curve (SUCRA) for the secondary outcomes for the treatment options for first 485 
trimester miscarriage. 486 
Treatments ranked first have lower likelihood to achieving adverse outcomes and higher 487 
likelihood of post-treatment satisfaction. Treatments with a higher SUCRA score have lower 488 
likelihood of achieving adverse outcomes and higher likelihood of post-treatment 489 
satisfaction. 490 
 491 
Supplementary Figure S1: Risk of bias in included trials on the treatment options for 492 
first trimester miscarriage. 493 
 494 
Supplementary Figure S2: Flow chart for the management of women with first 495 
trimester miscarriage. 496 
 497 
Supplementary Figure S3: Mixed evidence meta-analysis adjusted for inconsistency for 498 
treatment options for first trimester miscarriage. 499 
 500 
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Supplementary Figure S4: Funnel plot of the treatment effect for included trials on 501 
treatment options for first trimester miscarriage. 502 
 503 
Supplementary Figure S5: Mixed evidence network meta-analysis of blood transfusion 504 
following treatment options for first trimester miscarriage. (A) Network map. (B) Forest 505 
plot. (C) SUCRA.  506 
 507 
Supplementary Figure S6: Mixed evidence network meta-analysis of infection/pelvic 508 
inflammatory disease following treatment options for first trimester miscarriage. (A) 509 
Network map. (B) Forest plot. (C) SUCRA.  510 
 511 
Supplementary Figure S7: Mixed evidence network meta-analysis of serious 512 
complications following treatment options for first trimester miscarriage. (A) Network 513 
map. (B) Forest plot. (C) SUCRA.  514 
 515 
Supplementary Figure S8: Mixed evidence network meta-analysis of diarrhoea 516 
following treatment options for first trimester miscarriage. (A) Network map. (B) Forest 517 
plot. (C) SUCRA.  518 
 519 
Supplementary Figure S9: Mixed evidence network meta-analysis of vomiting following 520 
treatment options for first trimester miscarriage. (A) Network map. (B) Forest plot. (C) 521 
SUCRA.  522 
 523 
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Supplementary Figure S10: Mixed evidence network meta-analysis of nausea following 524 
treatment options for first trimester miscarriage. (A) Network map. (B) Forest plot. (C) 525 
SUCRA.  526 
 527 
Supplementary Figure 11: Mixed evidence network meta-analysis of fever following 528 
treatment options for first trimester miscarriage. (A) Network map. (B) Forest plot. (C) 529 
SUCRA.  530 
 531 
Supplementary Figure 12: Mixed evidence network meta-analysis of analgesia following 532 
treatment options for first trimester miscarriage. (A) Network map. (B) Forest plot. (C) 533 
SUCRA.  534 
 535 
Supplementary Figure 13: Mixed evidence network meta-analysis of women's 536 
satisfaction following treatment options for first trimester miscarriage. (A) Network 537 
map. (B) Forest plot. (C) SUCRA.  538 
 539 
 540 
Supplementary Table SI: Side-split analysis of inconsistency in the network of 541 
treatment options for first trimester miscarriage. 542 
 543 
Supplementary Table SII: Summary of risk of bias for included studies. 544 
 545 
Supplementary Table SIII: League table of effect estimates for secondary outcomes 546 
across treatment options for first trimester miscarriage. 547 
  548 
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